Jan 09, 2020 / 03:25PM GMT
Terence C. Flynn - Goldman Sachs Group Inc., Research Division - MD
Okay, great. Well, thanks for joining us, everybody. I'm Terence Flynn, the biopharma analyst here at Goldman Sachs, and we're very pleased to have Bristol-Myers Squibb with us this morning.
From the company, we have Giovanni Caforio, who is Chairman and CEO. Giovanni, thank you very much for being here this morning, really appreciate the time.
Giovanni Caforio - Bristol-Myers Squibb Company - Chairman of the Board & CEO
Thank you, Terence. Thanks. Good morning, everyone.
Questions and Answers:
Terence C. Flynn - Goldman Sachs Group Inc., Research Division - MDSo maybe to kick off, as everyone knows, this is about the 1-year anniversary of when you announced the Celgene deal. Would love for you to maybe recap the progress that's been made here since the announcement. And looking ahead, what are really the key drivers that we should all be focused on as we think about you guys generating a return from the acquisition?